SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation under Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Sun Pharma to acquire 11.28% stake in Zenotech from Daiichi Sankyo
After the acquisition, Sun Pharma's stake in Zenotech will increase from 57.56 per cent to 68.84 per cent, it added. SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Updates on Acquisition
As per letter attached.
Strong specialty sales and volumes keep it sunny for Sun Pharma
Rerating on the cards; the domestic business is expected to outperform Sun Pharma rallies 8% in 2 days on heavy volumes; stock nears 52-week high
Sun Pharma announced that its subsidiary Taro Pharmaceuticals USA Inc has completed the acquisition of subsidiary companies of Galderma SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Updates on Acquisition
Update on Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on March 03, 2022 for Dilip Shantilal Shanghvi SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation under Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby furnish the details of loss of share certificates/request for issue of duplicate share certificate reported by registered shareholder(s) of the Company, received from our Registrar and Transfer Agent, Link Intime India Private Limited on March 03, 2022. SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Schedule of Analyst/ Institutional Investor Meeting
Aurobindo, Sun Pharma recall products from US market
According to the USFDA, the Princeton-based Aurobindo Pharma USA Inc is recalling the affected lot due to "failed impurities/degradation specifications".